Definitive Contract 75N93021C00022
Award Date
5/17/21
Potential Completion Date
4/4/25
Potential Value
$27M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Spero Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
23
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>
This definitive cost-no-fee contract from the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awards $15.5 million to Entasis Therapeutics Inc. to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad spectrum activity against multidrug-resistant (MDR) gram-negative ESKAPE pathogens. The work directly responds to the 2019 NIAID Omnibus Broad Agency...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
This is a $26,427,820.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Revagenix Inc. The contract is for the advanced development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. This contract was awarded under a Broad Agency Announcement (BAA) solicitation that sought proposals for research and development of vaccines, therapeutics, and diagnostics...
This is a $237,994,127.86 definitive cost-reimbursement contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Hoffmann-La Roche Inc. for the "COMBATING MULTI-DRUG RESISTANCE AND ADDRESSING EMERGING BACTERIAL THREATS: DISCOVERY, CLINICAL DEVEL" program. The contract has a period of performance through September 30, 2027 and does not have a set-aside designation. The contract supports the agency's efforts to...
<p>This is a $98,144,230.00 definitive, cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to The Medicines Company on September 15, 2016. The contract is to advance the development of a portfolio of anti-infective programs. There is no set-aside designation indicated. The contract has an ultimate completion date of September 30, 2030.</p>
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...
<p>This is a $732,812.94 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Amplitude Therapeutics, Inc. on August 20, 2024. The contract is for the delivery of an AMPLITUDE THERAPEUTICS-A SPLIT-FORMULATED TRANS-AMPLIFYING RNA ENCODED ANTI-NEURAMINIDASE MONOCLONAL ANTIBODY and has an ultimate completion date of September 30, 2025. The contract does not utilize any set-aside designations.</p>
This is a $1,488,107.00 Firm Fixed Price Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Tetracore, Inc., a small business based in Rockville, Maryland. The contract is for the Phase II development of a rapid molecular assay for the point-of-care detection of Treponema pallidum, the causative agent of syphilis. This contract was awarded under the Small Business Innovation...